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Purpose: There have been studies on the relations between metabolic syndrome and colorectal cancer or on the relations 
between methylenetetrahydrofolate reductase (MTHFR) polymorphism and colorectal cancer, but reports on the relation-
ship between metabolic syndrome, MTHFR polymorphism and colorectal cancer all together are rare. The aim of this study 
is to find the interrelation between metabolic syndrome and MTHFR polymorphism in colorectal cancer.
Methods: This study investigated 255 colorectal cancer patients (cancer group) who underwent surgery in our hospital from 
March 2003 to December 2008 and compared those patients to 488 healthy patients (control group). The diagnostic crite-
rion for metabolic syndrome was based on the National Cholesterol Education Program-Adult Treatment Panel III (NCEP 
ATP III), and the MTHFR 677 polymorphism was analyzed.
Results: When colorectal cancer patients and patients in the control group were classified as MTHFR 677 subtypes, there 
was no difference between the two groups: CC 87 (34.1%), CT 134 (52.6%), and TT 34 (13.3%) for the cancer group and 
CC 145 (32.4%), CT 238 (53.1%), and TT 65 (14.5%) for the control group. Distributions of MTHFR 677C/T genotype and 
allele frequencies in the individuals with and without metabolic syndrome in the cancer group showed no differences. More-
over, we could find no differences in distributions of MTHFR 677C/T genotypes in the clinical and the biomedical vari-
ables of individuals with and without metabolic syndrome in the cancer group.
Conclusion: Our results show no relation between metabolic syndrome and MTHFR polymorphism in colorectal cancer. 
However, a further prospective study, based on a precise diagnostic criterion for metabolic syndrome, is needed.
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uting factors, including genetic tendency; environmental factors, 
such as dietary food, chemicals and pollution; and personal fac-
tors, such as reduced activity, obesity, hyperlipidemia, hyperinsu-
linemia, etc., which usually come together. In industrialized coun-
tries with aging societies, such risk factors have already been al-
ready identified. In certain patients, metabolic disorder might have 
a large influence in the development of colorectal cancer. In 1988, 
Reaven et al. [2] denominated those patients as insulin-resistant 
syndrome or Syndrome-X.
In 1998, the World Health Organization (WHO) defined the con-
cept of disorders as metabolic syndrome and suggested guidelines 
for diagnosis. Soon after, several groups, such as the National Cho-
lesterol Education Program-Adult Treatment Panel III (NCEP-ATP 
III) and the International Diabetes Foundation (IDF), have sug-
gested modified guidelines for making an accurate diagnosis [3, 
4]. In the past, metabolic syndrome was thought to be a risk fac-
tor related only with cardiovascular disease; however, it has also 
been considered to be directly and indirectly related to other dis-
INTRODUCTION
Recently, the incidence of colorectal cancer in Korea has been in-
creasing sharply, and it now ranks second among digestive organ 
malignancies. This is thought to be related to the rapid change in 
the life style of Koreans during past few decades due to industrial-
ization, increased amounts of high-calorie foods and fat, etc. [1]. 
Colorectal cancer seems to have complicated and diverse contrib-
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eases such as cancer [2, 3]. Sturmer et al. [5] studied 494 colorec-
tal cancer patients in a population of 22,071 and reported obesity 
and diabetes as risk factors causing colorectal cancer. Nevertheless, 
they could not find any relationship with hypertension and hyper-
cholesterolemia. Ju et al. [6], reported a domestic study with 558 
adult patients, in which metabolic syndrome might have increased 
the incidence of colorectal polyps, particularly in males.
There are two major pathways of colorectal carcinogenesis, the 
chromosomal instability pathway and the microsatellite instability 
pathway, which are based on epigenetic alterations, such as hyper-
methylation or hypomethylation, of genes. Methylenetetrahydro-
folate reductase (MTHFR) is one of the key enzymes in the process 
of folic acid metabolism, which is an important substrate for DNA 
synthesis. It has a major role in DNA methylation and has a close 
association with the synthesis of methionine. According to the poly-
morphism of the enzyme, the strength of the enzyme changes the 
reduction of methionine synthesis and DNA methylation. Based 
on several reports, this alteration seems to be associated with the 
carcinogenesis of the colorectum [7, 8].
Abnormal folic acid metabolism and hyperhomocysteinemia are 
known to increase the risk of coronary heart disease. Oron-Her-
man et al. [9] reported that hyperhomocysteinemia was an immi-
nent factor in metabolic syndrome in a mouse model study with 
polymorphism of MTHFR. Ellingrod et al. [10] said that patients 
with the T allele in MTHFR polymorphism had a 3.7-fold increased 
risk of having metabolic syndrome. On the contrary, the CC wild 
genotype exhibited a positive relationship for the schizophrenic 
patients having psychiatric drugs.
So far, reports studying the relationship between metabolic syn-
drome and MTHFR polymorphism in colorectal cancer patients 
are rare, and for that reason, this study was aimed at investigating 
the mutual relation between MTHFR polymorphism and meta-




We conducted a retrospective study on 255 colorectal cancer pa-
tients who underwent surgery from March 2003 to December 2008. 
For the control group, 448 healthy adults without any disease, such 
as cancer or metabolic disease, who showed similar ages and gen-
der distributions, were selected. The Institutional Review Board 
(IRB) of our Medical Center approved this genetic study in June 
2009.
Diagnosis of metabolic syndrome
In this study, we adopted the definition of metabolic syndrome 
from NCEP-ATP III. Patients having more than two of the follow-
ing factors were defined as having metabolic syndrome; obesity, 
body mass index (BMI) ≥ 25 kg/m
2; triglyceride, TG ≥ 150 mg/dL; 
high density cholesterol, male < 40 mg/dL and female < 50 mg/dL; 
fasting blood sugar, FBS ≥ 110 mg/dL; and blood pressure, systolic 
P ≥ 130 mm Hg or diastolic P ≥ 85 mm Hg. We used the BMI, in-
stead of abdominal circumference, as one of the diagnostic criteria.
Analysis of MTHFR polymorphism
Specimens were taken from leukocyte or formalin-fixed paraffin-
embedded specimens by using phenol/chloroform extraction meth-
ods, and the quality was adequate. The MTHFR genotype was ex-
amined using the PCR restriction fragment length polymorphism 
(RFLP) method. The DNA fragment containing MTHFR 677 C   
> T (Ala to Val) was amplified with a GeneAmp PCR machine 
(Perkin Elmer 2400, Foster City, CA, USA). DNA was replicated 
with human genomic DNA 200 ng, 1.5-mM MgCl₂, 0.2-M deoxy-
nucleotide triphosphate, 1 unit Taq Polymerase (TaKaRa, Madi-
son, WI, USA), and primer 100 pmol. The DNA sequence of the 
forward primer was 5´-GCACTTGAAGAGAAGGTGTC-3´, and 
that of the reverse primer was 5´-AGGACGGTGCGGTGAGA-
GTG-3´. The PCR was set at 35 cycles in 94°C for 30 seconds, 51°C 
for 30 seconds and 72°C for 30 seconds after a period of denatur-
ation for 5 minutes at 94°C. The terminal portion of the DNA was 
elongated at 72°C for 5 minutes. The products of PCR were precip-
itated in ethanol, disintegrated by Taq I restriction enzyme, and fi-
nally treated by using electrophoresis. The variant allele in the 677 
C→T polymorphism causes cytosine to be replaced with thymine 
in the final peptides. The TT variant type shows two bands, 173 bp 
and 30 bp, the CT heterozygote type shows three bands, 203 bp, 
173 bp and 30 bp, and the CC wild type shows a single band, 203 
bp, on electrophoresis. As a qualifying control, DNA from the lym-
phoblastoid cells with the three types of polymorphisms was used.
Data analysis
All calculations were done with Graphpad prism 4.0 (Graphpad 
Software Inc., San Diego, CA, USA), and categorical data were 
analyzed using the Fisher’s exact test and the t-test. The MedCalc 
ver. 10.4.0.0 (MedCalc Software Inc., Mariakerke, Belgium) was 
used for the ANOVA test and the chi-square test. Statistical signif-
icance was accepted at P ≤ 0.05.
RESULTS
Among the 255 cancer patients, the metabolic syndrome group in-
cluded 110 patients (43%) and the non-metabolic syndrome group 
included 145 patients (57%). A comparison of these two groups 
based on the diagnostic criteria of metabolic syndrome, including 
BMI, triglyceride, HDL cholesterol, fasting blood sugar, and sys-
tolic and diastolic blood pressure, showed statistically significant 
differences (Table 1). 
MTHFR 677 polymorphism in cancer patients was distributed as 
follows: 87 cases (34.1%) of CC type, 134 cases (52.6%) of CT type, 
and 34 cases (13.3%) of TT type. The control group showed a dis-
tribution similar to that of the cancer group with 145 cases (32.4%) 
of CC type, 238 cases (53.1%) of CT type and 65 cases (14.5%) of Journal of The Korean Society of
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TT type (Table 2). The distributions of MTHFR 677C/T genotype 
and allele frequencies in individuals with and without metabolic 
syndrome in the colorectal cancer patients group showed no defi-
nite differences (Table 3).
Clinical and biomedical variables of metabolic syndrome were 
individually analyzed according to 3 MTHFR 677C/T genotype 
in the cancer patient group, but the results showed no statistically 
significant differences (Table 4). Clinical and biomedical variables 
in individuals were reanalyzed according to the three genotypes 
in the two patients group with and without metabolic syndrome. 





No. (%) 110 (43.1) 145 (56.9) -
Age (yr)   67.2 ± 10.7   59.5 ± 12.7 <0.0001
Gender (M/F) 63/47 79/65 0.79
Body mass index 24.4 ± 3.2 21.9 ± 2.6 <0.0001
Triglyceride (mg/dL) 144.3 ± 70.7   98.1 ± 63.2 <0.0001
HDL-C (mg/dL)   37.1 ± 10.0   44.0 ± 12.5 <0.0001
FBS (mg/dL) 146.0 ± 54.4 113.3 ± 37.2 <0.0001
SBP (mm Hg) 144.3 ± 14.2 135.3 ± 15.7 <0.0001
DBP (mm Hg)   89.2 ± 10.4   84.4 ± 10.7    0.0004
HDL-C, high density lipoprotein; FBS, fasting blood sugar; SBP, systolic blood pres-
sure; DBP, diastolic blood pressure. P < 0.05.
Table 2. Comparison of MTHFR subtypes between the control and 
the colorectal cancer groups 
Parameter CC CT TT
Control 145 (32.4) 238 (53.1) 65 (14.5)
Colorectal cancer   87 (34.1) 134 (52.6) 34 (13.3)
Values are presented as number (%).
Methylenetetrahydrofolate reductase (MTHFR) 677 C > T subtypes: CC, CT and TT.
Table 3. Distribution of methylenetetrahydrofolate reductase (MTHFR) 
677C/T genotype and allele frequencies in individuals with and with-
out metabolic syndrome in colorectal cancer
Variable With MS  
(n = 110)
Without MS  
(n = 145)
P-value OR (95% CI)
Genotypes        
   CC   36 (32.7)   51 (35.2)    
   CT   60 (54.6)   74 (51.0) 0.678  0.87 (0.50-1.50)
   TT   14 (12.7)   20 (13.8) 1.000  1.00 (0.45-2.25)
Alleles        
   C 132 (60.0) 176 (60.7)    
   T   88 (40.0) 114 (39.3) 0.927  0.97 (0.67-1.39)
Values are presented as number (%).
MS, metabolic syndrome; OR, odds ratio; CI, confidence interval.
Table 4. Clinical and biomedical variables, analyzed by genotype, of 
metabolic syndrome in individuals with colorectal cancer (n = 255)
Parameter CC CT TT
No. (%) 87 (34.1) 134 (52.6) 34 (13.3)
Age (yr) 63.41 ± 11.60 62.35 ± 12.93 63.50 ± 13.41
Gender (M/F) 46/41 81/53 16/18
Body mass index 23.24 ± 3.151 23.07 ± 3.042 22.30 ± 3.553
Triglyceride (mg/dL) 119.8 ± 84.68 118.5 ± 64.10 111.8 ± 52.21
HDL-C (mg/dL) 40.12 ± 11.92 40.38 ± 11.78 43.47 ± 12.32
FBS (mg/dL) 128.5 ± 50.69 124.7 ± 42.96 135.7 ± 60.21
SBP (mm Hg) 139.5 ± 17.12 138.8 ± 15.17 140.0 ± 14.77
DBP (mm Hg) 86.90 ± 11.03 86.34 ± 11.14 86.47 ± 9.497
HDL-C, high density lipoprotein; FBS, fasting blood sugar; SBP, systolic blood pres-
sure; DBP, diastolic blood pressure.
Table 5. Clinical and biomedical variables, analyzed by genotype, in individuals with and without metabolic syndrome
MTHFR 677C/T genotype
With metabolic syndrome (n = 110) Without metabolic syndrome (n = 145)
CC CT TT CC/TT CC/CT Anova CC CT TT CC/TT CC/CT Anova
No. (%) 36 (32.7) 60 (54.6) 14 (12.7) 51 (35.2) 74 (51.0) 20 (13.8)
Gender (M/F) 18/18 38/22 7/7 28/23 43/31 9/11
Age (yr) 67.1 ± 11.3   66.9 ± 10.8 68.7 ± 9.5 0.64 0.90 0.84   60.7 ± 11.1   58.6 ± 13.3   59.8 ± 14.6 0.76 0.35 0.66
BMI (kg/m
2) 24.8 ± 3.1 24.6 ± 2.9 22.6 ± 4.0 0.04 0.76 0.07 22.1 ± 2.6 21.7 ± 2.5 22.0 ± 3.2 0.95 0.49 0.78
FBS (mg/dL) 144.1 ± 53.2 142.1 ± 50.1 167.4 ± 72.3 0.21 0.85 0.28 117.5 ± 46.2 110.3 ± 29.3 113.6 ± 38.1 0.73 0.29 0.57
TG (mg/dL) 136.4 ± 64.4 150.8 ± 76.3 136.9 ± 62.5 0.97 0.34 0.57 108.2 ± 95.3   92.3 ± 34.9   94.3 ± 35.6 0.52 0.19 0.37
HDL-C (mg/dL) 36.5 ± 7.9   37.8 ± 11.6 35.8 ± 7.0 0.80 0.58 0.76   43.5 ± 13.9   42.8 ± 11.4   50.5 ± 12.0 0.12 0.77 0.13
SBP (mm Hg) 143.8 ± 13.4 144.7 ± 14.6 144.3 ± 15.5 0.90 0.76 0.95 136.5 ± 18.8 134.1 ± 13.9 137.0 ± 13.8 0.91 0.41 0.61
DBP (mm Hg) 88.3 ± 9.4   90.3 ± 11.0   87.1 ± 10.6 0.70 0.36 0.48   85.8 ± 12.0   83.1 ± 10.1 86.0 ± 8.8 0.96 0.16 0.29
BMI, body mass index; TG, triglyceride; HDL-C, high density lipoprotein; FBS, fasting blood sugar; SBP, systolic blood pressure; DBP, diastolic blood pressure.Journal of The Korean Society of
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However, the results did not indicate any statistically significant 
differences (Table 5).
DISCUSSION
Metabolic syndrome is referred to as the grouping phenomenon 
of several metabolic risk factors, such as hypertension, diabetes, 
obesity, hyperlipidemia, etc., that mainly cause cardiovascular dis-
ease. Although diagnostic criteria for metabolic syndrome have 
been changing with different expert groups since the first guide-
lines of the WHO in 1998, insulin resistance and obesity have al-
ways been considered as important basic factors [3]. Metabolic syn-
drome, the well-known major risk factor of coronary heart disease, 
has now been studied for its relationship to other diseases, includ-
ing cancer [3, 4].
In colorectal cancer studies, not only individual metabolic factor 
but also other related factors, such as low physical activity, abdom-
inal obesity, etc., were evaluated for their possible relation to can-
cer. For example, Frezza et al. [11] insisted that being overweight 
was closely related to colon cancer and that the reduction of weight 
was important for decreasing the risk of cancer. Chang and Ulrich 
[12] reported that a high level of blood sugar affected the carcino-
genesis of the colon. Sturmer et al. [5], in their 19-year following-
up study for one healthy group, reported that being overweight 
and having diabetes were more closely related to colon cancer than 
other metabolic factors. The prevalence of metabolic syndrome in 
the adult population older than 50 years was reported to be approx-
imately 45% in the United States and 16.3% in South Korea [6, 13]. 
On the other hand, the prevalence of metabolic syndrome in co-
lon cancer patients was high in our study, approaching 43%.
Playing an important role for not only DNA synthesis but also 
DNA methylation, MTHFR takes part in the metabolism of folic 
acid, resulting in the formation of S-adenosyl methionine, which 
is mainly involved in the methylation. There are two major poly-
morphisms of MTHFR, 677C (alanine)→T (valine) and 1298 A 
(glutamate)→C (alanine) substitutions. The alterations from these 
polymorphisms result in decreased efficacy of the enzyme, which 
might subsequently decrease DNA methylation and may be re-
lated to colorectal carcinogenesis.
The TT subtype decreases the enzyme strength by about 30% and 
causes hypomethylation. The TT subtype affects the blood level of 
folic acid, and it has been reported to increase the risk of colon can-
cer, especially in heavy alcohol drinkers with a low level of folic 
acid. The TT subtype was contrarily reported not only to decrease 
the risk of colon cancer but also to increase the proportion of co-
lon cancer patients with microsatellite instability [14-16]. In this 
study, we couldn’t find any difference of frequency for the MTHFR 
polymorphism between the colorectal cancer group and the healthy 
control group, with the colorectal cancer group showing 13.3% TT 
subtype and the healthy control group showing 14.5% TT subtype. 
This result is similar to our previous report, showing 11.5% TT sub-
type in the colon cancer group and 14.4% in the control group [7].
Sporadic microsatellite instability is thought to be caused by pro-
moter hypermethylation of the MLH1 mismatch repair gene. In 
the case of a low level of folic acid concentration, the TT subtype 
causes a large extent of hypomethylation and a consequent altera-
tion of gene expression.
We have mentioned the TT subtype as a prognostic factor for 
colon cancer [7]; on the other hand, we were able to find several 
interesting articles about studies on the TT subtype for other fields. 
For example, Ellingrod et al. [10] reported that patients in the schizo-
phrenic psychiatric patient group with the TT subtype had a 3.7-
fold increased risk of metabolic syndrome and suggested that this 
type seems to increase insulin resistance and abdominal obesity.
As mentioned earlier, on database such as PubMed, we couldn’t 
find any reports similar to ours on the relationships of colon can-
cer, metabolic syndrome and MTHFR polymorphism all together, 
although there were several reports that individually studied only 
the relation between colon cancer and metabolic syndrome, and 
only the relation between colon cancer and MTHFR polymor-
phism. In this study, the distributions of MTHFR polymorphism 
based on the presence or absence of metabolic syndrome did not 
show different patterns, and even the frequencies of the T allele 
showed similar patterns. As a result, we could find no relation be-
tween metabolic syndrome and MTHFR polymorphism in colon 
cancer patients.
The reason we did not have any significant result, despite our large 
sample size compared to that of Ellingrod et al. [10], who obtained 
statistically significant results, is thought to be due to the particu-
lar patient group, i.e., psychiatric patients, Ellingrod et al.’s. We as-
sume that medications or other clinical factors might have contrib-
utes to their being more vulnerable to metabolic syndrome.
In order to get rid of confounding bias after surgery, we conducted 
this study only with patients who had been diagnosed prior to sur-
gery as having metabolic syndrome. However, the individual fac-
tors of metabolic syndrome (hypertension, blood sugar level, cho-
lesterol level, etc.) could have varied according to the clinical con-
dition or the situation of the patients, and even the accuracy of 
medical records might be doubted in this retrospective study.
As a factor of metabolic syndrome, we adopted the BMI, instead 
of the abdominal circumference, because the abdominal circum-
ference is often omitted on medical records. Especially, Korean 
people tend to have abdominal obesity even in the normal range 
of height and weight, and whether the BMI or the abdominal cir-
cumference is chosen for the diagnosis of metabolic syndrome 
seems to affect the results of the study. Besides, there are different 
criteria for the diagnosis of metabolic syndrome and agreement 
on criteria for a definite diagnosis has not yet been reached.
We think that a large and prospective study might be needed in 
order to achieve accurate and meaningful results. If there were to 
be a significant difference between MTHFR polymorphism in 
metabolic syndrome and that in colon cancer, then the compari-
son of survival based on polymorphism would be meaningful. 
Even though we have a few other reports for comparison, we have Journal of The Korean Society of
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failed to achieve significant results in this study. Still, we believe 
that this study itself to be meaningful as a first report studying the 
relationship between MTHFR polymorphism and metabolic syn-
drome in colorectal cancer.
In conclusion, the results of this study revealed no relation be-
tween metabolic syndrome and MTHFR polymorphism in colorec-
tal cancer. Although we could not elicit such a relationship, a fur-
ther prospective study based on precise diagnostic criteria for met-
abolic syndrome may be able to establish such a relationship.
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